Monocentric retrospective analysis of locally advanced and inflammatory breast cancer (IBC) patients (pts) having received a neoadjuvant chemotherapy with docetaxel (D) and anthracyclines

Abstract

10743 Background: Anthracycline-based neoadjuvant therapy is a standard treatment, but use of D in the preoperative setting increases clinical and pathological response, as monotherapy or as part of combination chemotherapy for preoperative setting. Our purpose was to assess the efficacy in pts who were treated with D and anthracyclines (doxorubicine A or epirubicine E) in neoadjuvant setting. Methods: Pts with histologically proven, unilateral breast cancer, T2-T4, N0-N2, M0 tumors received every 3 weeks an association of D and A or E, according to different schedules. This retrospective analysis was designed to evaluate the clinical and pathological response rate of this association. Results: Between October 1999 and December 2003 45 pts (44 women and 1 man) were treated with associations: 39 D and E or A, 3 D, A and vinorelbine, 1 D, A and capecitabine (X), 1 D, A and trastuzumab (H), 1 D, X and H; median age 47 [27–71] years; median number of cycles of chemotherapy: 4 [3–6]; median tumour diameter: 50 mm [20–150] with 6 IBC; median radiological size: mammography 32 mm [11–90], echography 32.5 mm [8–90]; tumour stage: 15 T2N0 (33%), 12 T2N1 (27%), 7 T3N0 (15%), 2 T3N1 (4%), 1 T3N2 (2%), 1 T4bN1 (2%), 1 T4cN2 (2%), 3 T4dN0 (7%), 2 T4dN2 (4%), 1 T4N0 (2%); tumour grade: 22 grade II (49%), 22 grade III (49%), 1 unknown; tumour histology : 31 ductal carcinoma (69%), 13 lobular carcinoma (29%), 1 mucineous carcinoma (2%); hormonal status: 29 positive (64%), 16 negative (36%). Among these pts, 13 had nodal curage concomitant with diagnosis biopsy. All pts were evaluable for clinical response: ORR was 91% (18 complete response CR 40%, 23 partial response PR 51%. Histological response was available in 32 pts: Chevallier classification pCR grade 1–2: 5 (11%), Sataloff TA /NA-NB 5 (16%). On 32 pts with postchemotherapy nodal curage, 16 had negative nodal disease. On these 16 pts, 8 were N0 at diagnosis, 5 N1 and 3 N2. Conclusions: Association of D and anthracyclines in breast carcinoma exhibits a high pathological response rate. No significant financial relationships to disclose.